The effect of oseltamivir use in critically ill patients with COVID-19: A multicenter propensity score-matched study
CONCLUSION: Oseltamivir was associated with faster viral clearance and shorter MV duration without safety concerns in critically ill COVID-19 patients.PMID:37256102 | PMC:PMC10203981 | DOI:10.1016/j.jsps.2023.05.006 (Source: Cancer Control)
Source: Cancer Control - May 31, 2023 Category: Cancer & Oncology Authors: Ohoud Aljuhani Ghazwa B Korayem Ali F Altebainawi Meshal S Alotaibi Noura A Alrakban Ragia H Ghoneim Ramesh Vishwakarma Abdulrahman I Al Shaya Shmeylan Al Harbi Jawaher Gramish Dahlia M Almutairi Ghada Alqannam Faisal F Alamri Abdullah F Alharthi Mashael Source Type: research
Efficacy of favipiravir against influenza virus resistant to both baloxavir and neuraminidase inhibitors
ConclusionsOur findings indicate that favipiravir should be used to treat patients with suspected baloxavir-resistant virus infection. (Source: Journal of Antimicrobial Chemotherapy)
Source: Journal of Antimicrobial Chemotherapy - May 20, 2023 Category: Microbiology Source Type: research
Artesunate inhibits PDE4 leading to intracellular cAMP accumulation, reduced ERK/MAPK signaling, and blockade of influenza A virus vRNP nuclear export
Antiviral Res. 2023 May 14:105635. doi: 10.1016/j.antiviral.2023.105635. Online ahead of print.ABSTRACTInfluenza A viruses (IAV) have been a major cause of mortality. Given the potential for future deadly pandemics, effective drugs are needed for the treatment of severe influenzas, such as those caused by H5N1 IAV. The anti-malaria drugs artemisinin and its derivates, including artesunate (AS), have been reported to have broad antiviral activities. Here, we showed AS's antiviral activity against H5N1, H1N1, H3N2 and oseltamivir-resistant influenza A(H1N1)virus in vitro. Moreover, we showed that AS treatment significantly p...
Source: Antiviral Research - May 16, 2023 Category: Virology Authors: Xia Yang Feixiang Long Weixin Jia Mingxin Zhang Guanming Su Ming Liao Zhenling Zeng Weisan Chen Jianxin Chen Source Type: research
Artesunate inhibits PDE4 leading to intracellular cAMP accumulation, reduced ERK/MAPK signaling, and blockade of influenza A virus vRNP nuclear export
Antiviral Res. 2023 May 14:105635. doi: 10.1016/j.antiviral.2023.105635. Online ahead of print.ABSTRACTInfluenza A viruses (IAV) have been a major cause of mortality. Given the potential for future deadly pandemics, effective drugs are needed for the treatment of severe influenzas, such as those caused by H5N1 IAV. The anti-malaria drugs artemisinin and its derivates, including artesunate (AS), have been reported to have broad antiviral activities. Here, we showed AS's antiviral activity against H5N1, H1N1, H3N2 and oseltamivir-resistant influenza A(H1N1)virus in vitro. Moreover, we showed that AS treatment significantly p...
Source: Antiviral Research - May 16, 2023 Category: Virology Authors: Xia Yang Feixiang Long Weixin Jia Mingxin Zhang Guanming Su Ming Liao Zhenling Zeng Weisan Chen Jianxin Chen Source Type: research
Viruses, Vol. 15, Pages 1154: In Vivo Antiviral Activity of Baloxavir against PA/I38T-Substituted Influenza A Viruses at Clinically Relevant Doses
In conclusion, baloxavir acid demonstrated dose-dependent antiviral effects comparable to that of oseltamivir phosphate, even though the degree of lung virus titer reduction was diminished in animal models infected with PA/I38T-substituted strains. (Source: Viruses)
Source: Viruses - May 11, 2023 Category: Virology Authors: Takayuki Kuroda Keita Fukao Shinpei Yoshida Ryoko Oka Kaoru Baba Yoshinori Ando Keiichi Taniguchi Takeshi Noshi Takao Shishido Tags: Article Source Type: research
The efficacy and mechanism of salmeterol against influenza A virus in vitro and in vivo
Int Immunopharmacol. 2023 May 7;119:110226. doi: 10.1016/j.intimp.2023.110226. Online ahead of print.ABSTRACTInfluenza A virus (IAV) is the most harmful pathogen to human beings among the various subtypes of influenza virus, which can lead to immune response, cause serious inflammation and damage to the lung. Salmeterol is a candidate compound with anti-IAV activity screened by virtual network proximity predication. In this paper, we further evaluated the pharmacodynamics of salmeterol against IAV in vivo and in vitro. The results showed that salmeterol could inhibit the activity of three IAV strains (H1N1, H3N2 and H1N1 s...
Source: International Immunopharmacology - May 9, 2023 Category: Allergy & Immunology Authors: Jun Zhao Lvjie Xu Yiming Bai Chao Wang Pengfei Guo Zhe Wang Guanhua Du Ailin Liu Source Type: research
The efficacy and mechanism of salmeterol against influenza A virus in vitro and in vivo
Int Immunopharmacol. 2023 May 7;119:110226. doi: 10.1016/j.intimp.2023.110226. Online ahead of print.ABSTRACTInfluenza A virus (IAV) is the most harmful pathogen to human beings among the various subtypes of influenza virus, which can lead to immune response, cause serious inflammation and damage to the lung. Salmeterol is a candidate compound with anti-IAV activity screened by virtual network proximity predication. In this paper, we further evaluated the pharmacodynamics of salmeterol against IAV in vivo and in vitro. The results showed that salmeterol could inhibit the activity of three IAV strains (H1N1, H3N2 and H1N1 s...
Source: International Immunopharmacology - May 9, 2023 Category: Allergy & Immunology Authors: Jun Zhao Lvjie Xu Yiming Bai Chao Wang Pengfei Guo Zhe Wang Guanhua Du Ailin Liu Source Type: research
Impact of the multiplex molecular FilmArray Respiratory Panel on antibiotic prescription and clinical management of immunocompromised adults with suspected acute respiratory tract infections: A retrospective before-after study
This study aimed to assess the impact of the implementation of a rapid multiplex molecular FilmArray Respiratory Panel (FRP) on the medical management of immunocompromised patients from a community general hospital. We conducted a single-center, retrospective, and before-after study. Two periods were evaluated: before the implementation of the FRP (pre-FRP) from April 2017 to May 2018 and after the implementation of the FRP (post-FRP) from January to July 2019. The inclusion criteria were immunocompromised patients over 18 years of age with suspected acute respiratory illness tested by conventional diagnostic methods (pre-...
Source: Revista Argentina de Microbiologia - May 1, 2023 Category: Microbiology Authors: Silvina Bergese B árbara Fox Natalia Garc ía-Allende Mar ía Elisa Elisiri Ana Elizabeth Schneider Juan Ruiz Sol Gonzalez-Fraga Viviana Rodriguez Liliana Fernandez-Canigia Source Type: research
